학술논문
Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials.
Document Type
Academic Journal
Author
Jeter JM; Department of Medicine, Divisions of Genetics and Oncology, The Ohio State University, Columbus, Ohio.; Bowles TL; Department of Surgery, Intermountain Health Care, Huntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, Utah.; Curiel-Lewandrowski C; Department of Medicine, The University of Arizona Cancer Center, Tucson, Arizona.; Swetter SM; Department of Dermatology, Pigmented Lesion and Melanoma Program, Stanford University Medical Center Cancer Institute, Veterans Affairs Palo Alto Health Care System, Palo Alto, California.; Filipp FV; Systems Biology and Cancer Metabolism, Program for Quantitative Systems Biology, University of California Merced, Merced, California.; Abdel-Malek ZA; Department of Dermatology, University of Cincinnati, Cincinnati, Ohio.; Geskin LJ; Department of Dermatology, Cutaneous Oncology Center, Columbia University Medical Center, New York, New York.; Brewer JD; Department of Dermatologic Surgery, Mayo Clinic Minnesota, Rochester, Minnesota.; Arbiser JL; Department of Dermatology, Emory University School of Medicine, Atlanta, Georgia.; Division of Dermatology, Veterans Affairs Medical Center, Atlanta, Georgia.; Gershenwald JE; Departments of Surgical Oncology and Cancer Biology, Melanoma and Skin Cancer Center, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Chu EY; Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.; Kirkwood JM; Melanoma and Skin Cancer Program, Department of Medicine, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania.; Box NF; Department of Dermatology, University of Colorado Anschutz Medical Campus, Aurora, Colorado.; Dermatology Service, U.S. Department of Veterans Affairs, Eastern Colorado Health Care System, Denver, Colorado.; Department of Epidemiology, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, Colorado.; Funchain P; Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio.; Fisher DE; Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts.; Kendra KL; Department of Internal Medicine, Medical Oncology Division, The Ohio State University, Columbus, Ohio.; Marghoob AA; Memorial Sloan Kettering Skin Cancer Center and Department of Dermatology, Memorial Sloan Kettering Cancer Center, New York, New York.; Chen SC; Department of Dermatology, Emory University School of Medicine, Atlanta, Georgia.; Division of Dermatology, Veterans Affairs Medical Center, Atlanta, Georgia.; Ming ME; Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.; Albertini MR; Department of Medicine, University of Wisconsin, School of Medicine and Public Health, University of Wisconsin Carbone Cancer Center, William S. Middleton Memorial Veterans Hospital, Madison, Wisconsin.; Vetto JT; Division of Surgical Oncology, Oregon Health & Science University, Portland, Oregon.; Margolin KA; Department of Medical Oncology, City of Hope National Medical Center, Duarte, California.; Pagoto SL; Department of Allied Health Sciences, UConn Institute for Collaboration in Health, Interventions, and Policy, University of Connecticut, Storrs, Connecticut.; Hay JL; Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, New York.; Grossman D; Departments of Dermatology and Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.; Ellis DL; Department of Dermatology, Vanderbilt University Medical Center and Division of Dermatology, Vanderbilt Ingram Cancer Center, Nashville, Tennessee.; Department of Medicine, Tennessee Valley Healthcare System, Nashville Veterans Affairs Medical Center, Nashville, Tennessee.; Kashani-Sabet M; Center for Melanoma Research and Treatment, California Pacific Medical Center, San Francisco, California.; Mangold AR; Department of Dermatology, Mayo Clinic, Scottsdale, Arizona.; Markovic SN; Department of Hematology and Oncology, Mayo Clinic, Rochester, Minnesota.; Meyskens FL Jr; Nelson KC; Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Powers JG; Department of Dermatology, University of Iowa, Iowa City, Iowa.; Robinson JK; Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.; Sahni D; Department of Dermatology, Boston Medical Center, Boston, Massachusetts.; Sekulic A; Department of Dermatology, Mayo Clinic, Scottsdale, Arizona.; Sondak VK; Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center, Tampa, Florida.; Departments of Oncologic Sciences and Surgery, University of South Florida Morsani College of Medicine, Tampa, Florida.; Wei ML; Department of Dermatology, University of California, San Francisco, San Francisco, California.; Dermatology Service, San Francisco Veterans Affairs Medical Center, San Francisco, California.; Zager JS; Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center, Tampa, Florida.; Department of Sarcoma, H. Lee Moffitt Cancer Center, Tampa, Florida.; Dellavalle RP; Department of Dermatology, University of Colorado Anschutz Medical Campus, Aurora, Colorado.; Dermatology Service, U.S. Department of Veterans Affairs, Eastern Colorado Health Care System, Denver, Colorado.; Department of Epidemiology, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, Colorado.; Thompson JA; Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington.; Weinstock MA; Center for Dermatoepidemiology, Veterans Affairs Medical Center, Providence, Rhode Island.; Department of Dermatology, Brown University, Providence, Rhode Island.; Department of Epidemiology, Brown University, Providence, Rhode Island.; Department of Dermatology, Rhode Island Hospital, Providence, Rhode Island.; Leachman SA; Department of Dermatology, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon.; Cassidy PB; Department of Dermatology, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon.
Source
Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE
Subject
Language
English
Abstract
Recent progress in the treatment of advanced melanoma has led to unprecedented improvements in overall survival and, as these new melanoma treatments have been developed and deployed in the clinic, much has been learned about the natural history of the disease. Now is the time to apply that knowledge toward the design and clinical evaluation of new chemoprevention agents. Melanoma chemoprevention has the potential to reduce dramatically both the morbidity and the high costs associated with treating patients who have metastatic disease. In this work, scientific and clinical melanoma experts from the national Melanoma Prevention Working Group, composed of National Cancer Trials Network investigators, discuss research aimed at discovering and developing (or repurposing) drugs and natural products for the prevention of melanoma and propose an updated pipeline for translating the most promising agents into the clinic. The mechanism of action, preclinical data, epidemiological evidence, and results from available clinical trials are discussed for each class of compounds. Selected keratinocyte carcinoma chemoprevention studies also are considered, and a rationale for their inclusion is presented. These data are summarized in a table that lists the type and level of evidence available for each class of agents. Also included in the discussion is an assessment of additional research necessary and the likelihood that a given compound may be a suitable candidate for a phase 3 clinical trial within the next 5 years.
(© 2018 American Cancer Society.)
(© 2018 American Cancer Society.)